Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Sal Med S.R.L.

Research site

Romania Block P7 Scara E Etaj P, Strada Traian, 110424 Pitesti, Romania

  • 7 trials recruiting
  • Atrial fibrillation · Cardiac failure · Arteriosclerosis
  • Adult patients

About Specializations

Sal Med S.R.L. in Pitesti, Romania specialises in clinical trials of conditions such as Atrial fibrillation, Cardiac failure, Arteriosclerosis, Acute coronary syndrome, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Research

The medical center is at the forefront of cardiovascular research, focusing on innovative treatments for atherosclerotic cardiovascular disease (ASCVD). The center's research aims to improve patient outcomes by exploring new therapeutic avenues.

  • Prevention of cardiovascular events
  • Innovative lipid-lowering therapies
  • Advanced management of vascular diseases

Through its cutting-edge research, the center contributes significantly to the understanding and management of cardiovascular conditions, offering hope for improved quality of life for patients worldwide.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Block P7 Scara E Etaj P, Strada Traian110424 PitestiRomania
Open in maps ↗
Recruiting now
7 trials
Conditions studied
17

More sites in PitestiRomania

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

20 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Atrial fibrillation

Recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:RomaniaRomania
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Cardiac failure chronic+1

Recruiting

Study on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Derisomaltose
  • Sponsor:Pharmacosmos A/S

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Recruiting
Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Familial hypertriglyceridaemia+1

Not recruiting

Study of ISIS 678354 for Patients with Severe High Triglycerides

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.